NASDAQ:JAZZ

Jazz Pharmaceuticals Competitors

$168.90
+0.51 (+0.30 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$167.40
Now: $168.90
$170.16
50-Day Range
$160.45
MA: $166.19
$173.15
52-Week Range
$101.81
Now: $168.90
$178.64
Volume512,738 shs
Average Volume719,861 shs
Market Capitalization$9.51 billion
P/E Ratio53.28
Dividend YieldN/A
Beta1.08

Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying JAZZ stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Jazz Pharmaceuticals, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Jazz Pharmaceuticals and Johnson & Johnson's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.40$523.37 million$14.6011.57
Johnson & Johnson$82.06 billion5.21$15.12 billion$8.6818.69

Johnson & Johnson has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Jazz Pharmaceuticals and Johnson & Johnson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111602.83
Johnson & Johnson031102.79

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Johnson & Johnson has a consensus target price of $182.6154, indicating a potential upside of 12.56%. Given Johnson & Johnson's higher probable upside, analysts plainly believe Johnson & Johnson is more favorable than Jazz Pharmaceuticals.

Risk & Volatility

Jazz Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Jazz Pharmaceuticals and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Johnson & Johnson21.01%34.64%13.40%

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Jazz Pharmaceuticals and Pfizer's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.40$523.37 million$14.6011.57
Pfizer$51.75 billion4.16$16.27 billion$2.9513.07

Pfizer has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Jazz Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.4% of Pfizer shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Jazz Pharmaceuticals and Pfizer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111602.83
Pfizer010302.23

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Pfizer has a consensus target price of $38.5714, indicating a potential upside of 0.00%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Jazz Pharmaceuticals is more favorable than Pfizer.

Profitability

This table compares Jazz Pharmaceuticals and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Pfizer17.85%24.88%9.32%

Summary

Jazz Pharmaceuticals beats Pfizer on 10 of the 14 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Merck & Co., Inc.'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.40$523.37 million$14.6011.57
Merck & Co., Inc.$46.84 billion4.19$9.84 billion$5.1914.93

Merck & Co., Inc. has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jazz Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Institutional & Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and Merck & Co., Inc., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111602.83
Merck & Co., Inc.021102.85

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Merck & Co., Inc. has a consensus target price of $96.2727, indicating a potential upside of 24.27%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Jazz Pharmaceuticals.

Profitability

This table compares Jazz Pharmaceuticals and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Merck & Co., Inc.24.33%53.83%16.83%

Jazz Pharmaceuticals (NASDAQ:JAZZ) and AbbVie (NYSE:ABBV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and AbbVie's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.40$523.37 million$14.6011.57
AbbVie$33.27 billion5.72$7.88 billion$8.9412.07

AbbVie has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jazz Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Institutional & Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.5% of AbbVie shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and AbbVie, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111602.83
AbbVie121302.75

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. AbbVie has a consensus target price of $115.75, indicating a potential upside of 7.27%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than AbbVie.

Profitability

This table compares Jazz Pharmaceuticals and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
AbbVie18.16%439.24%13.22%

Summary

Jazz Pharmaceuticals beats AbbVie on 8 of the 14 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Eli Lilly and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.40$523.37 million$14.6011.57
Eli Lilly and$22.32 billion8.13$8.32 billion$6.0431.33

Eli Lilly and has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jazz Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Institutional & Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and Eli Lilly and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111602.83
Eli Lilly and041102.73

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Eli Lilly and has a consensus target price of $196.40, indicating a potential upside of 3.78%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Eli Lilly and.

Profitability

This table compares Jazz Pharmaceuticals and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Eli Lilly and24.01%166.45%15.18%

Summary

Jazz Pharmaceuticals beats Eli Lilly and on 8 of the 14 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Bristol-Myers Squibb's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.40$523.37 million$14.6011.57
Bristol-Myers Squibb$26.15 billion5.59$3.44 billion$4.6913.96

Bristol-Myers Squibb has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jazz Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Institutional & Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and Bristol-Myers Squibb, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111602.83
Bristol-Myers Squibb021312.94

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Bristol-Myers Squibb has a consensus target price of $74.60, indicating a potential upside of 13.96%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Jazz Pharmaceuticals.

Profitability

This table compares Jazz Pharmaceuticals and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Bristol-Myers Squibb-0.11%27.48%10.77%

Summary

Jazz Pharmaceuticals beats Bristol-Myers Squibb on 8 of the 15 factors compared between the two stocks.


Jazz Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$162.24+1.1%$427.13 billion$82.06 billion25.51Upcoming Earnings
News Coverage
Pfizer logo
PFE
Pfizer
2.3$38.57+2.5%$215.13 billion$51.75 billion24.88Analyst Revision
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$77.47+1.0%$196.03 billion$46.84 billion17.14Increase in Short Interest
Analyst Revision
News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.91+0.9%$190.44 billion$33.27 billion22.81Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.1$189.25+1.8%$181.49 billion$22.32 billion30.92Analyst Revision
News Coverage
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$65.46+1.6%$146.23 billion$26.15 billion-595.04Analyst Upgrade
Decrease in Short Interest
Analyst Revision
Zoetis logo
ZTS
Zoetis
2.2$167.63+1.3%$79.62 billion$6.26 billion49.74Increase in Short Interest
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.87+0.5%$25.42 billionN/A0.00Dividend Announcement
Insider Selling
Increase in Short Interest
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.27+0.3%$20.90 billion$1.30 billion25.48Insider Selling
Perrigo logo
PRGO
Perrigo
2.3$41.62+1.1%$5.56 billion$4.84 billion-693.55
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00+1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07+5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77+0.7%$2.67 billion$306.49 million25.58
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70+0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Endo International logo
ENDP
Endo International
1.3$6.26+3.4%$1.44 billion$2.91 billion-9.21
Omeros logo
OMER
Omeros
1.4$18.37+0.2%$1.14 billion$111.81 million-7.72News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00+3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Gap Down
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.01+1.4%$375.61 million$16.54 million-3.26News Coverage
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.42+1.5%$344.95 million$111.39 million24.43News Coverage
Lannett logo
LCI
Lannett
2.0$4.76+0.2%$197.07 million$545.74 million-6.61
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.28+1.2%$171.45 million$15.96 million-2.59
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$2.99+1.7%$44.61 million$47.53 million-13.59
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.